Putative neuroprotective agents in neuropsychiatric disorders

@article{Dodd2013PutativeNA,
  title={Putative neuroprotective agents in neuropsychiatric disorders},
  author={Seetal Dodd and Michael Maes and George Anderson and Olivia M. Dean and Michael Berk},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2013},
  volume={42},
  pages={135-145}
}
  • S. Dodd, Michael Maes, +2 authors M. Berk
  • Published 5 April 2013
  • Psychology, Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
In many individuals with major neuropsychiatric disorders including depression, bipolar disorder and schizophrenia, their disease characteristics are consistent with a neuroprogressive illness. This includes progressive structural brain changes, cognitive and functional decline, poorer treatment response and an increasing vulnerability to relapse with chronicity. The underlying molecular mechanisms of neuroprogression are thought to include neurotrophins and regulation of neurogenesis and… Expand
Neurobiology and Therapeutic Potential of Cyclooxygenase-2 (COX-2) Inhibitors for Inflammation in Neuropsychiatric Disorders
TLDR
The evidence reviewed here suggests cyclooxygenase-2 inhibitors, and in particular celecoxib, may indeed assist in treating the symptoms of neuropsychiatric disorders; however, further studies are required to assess appropriate illness stage-related indication. Expand
Melatonin in the Etiology, Pathophysiology, and Management of Schizophrenia
TLDR
It is proposed that melatonin interacts with the tryptophan catabolite pathway, known to be altered in schizophrenia, and may improve not only the quality of life but also the drastic decrease in life expectancy in schizophrenia patients. Expand
Biological hypotheses and biomarkers of bipolar disorder
TLDR
Current biological hypotheses of BD are summarized, including related pathophysiological processes and key biomarkers, which have been associated with changes in genetics, systems of neurotransmitter and neurotrophic factors, neuroinflammation, autoimmunity, cytokines, stress axis activity, chronobiology, oxidative stress, and mitochondrial dysfunctions. Expand
Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview.
  • E. Ochoa
  • Medicine
  • Cellular and molecular neurobiology
  • 2021
TLDR
It is not known whether Li+-induced neuroprotection is related to the inhibition of its putative molecular targets in a BD episode: the enzymes inositol-monophosphatase, (IMPase), glycogen-synthase-kinase 3β (GSK3), and Protein kinase C (PKC), and whether these neuroprotective mechanisms are correlated with Li+'s clinical efficacy in maintaining mood stability. Expand
Psychopharmacological Treatment of Neurocognitive Deficits in People with Schizophrenia: A Review of Old and New Targets
TLDR
Overall, existing clinical trials provide little reason to be enthusiastic about the benefits of psychopharmacological agents at enhancing neurocognition in schizophrenia—a state of affairs that may reflect the inadequacy of single neurotransmitter or receptor models. Expand
Beyond the therapeutic shackles of the monoamines: New mechanisms in bipolar disorder biology
ABSTRACT Multiple novel biological mechanisms putatively involved in the etiology of bipolar disorders are being explored. These include oxidative stress, altered glutamatergic neurotransmission,Expand
Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries
TLDR
Outside of the dopaminergic model, the potential pathogenesis of schizophrenia has yet to be fully elucidated, but common themes include neuropil shrinkage, the development of abnormal neuronal circuitry, and a chronic inflammatory state which further disrupts neuronal function. Expand
ROS and Brain Diseases: The Good, the Bad, and the Ugly
TLDR
The Janus-faced properties of reactive oxygen species are reviewed and modulation of the prooxidant-antioxidant balance provides a therapeutic option which can be used to improve neuroprotection in response to oxidative stress. Expand
New Targets for Schizophrenia Treatment beyond the Dopamine Hypothesis
  • A. Yang, S. Tsai
  • Medicine
  • International journal of molecular sciences
  • 2017
TLDR
This review attempts to address novel treatment targets beyond the dopamine hypothesis, including glutamate, serotonin, acetylcholine, GABA, and inflammatory cytokines, and outlines that these treatment targets can be possibly integrated with novel treatment strategies aimed at different symptoms or phases of the illness. Expand
Obesity and psychiatric disorders: Commonalities in dysregulated biological pathways and their implications for treatment
TLDR
It is proposed that weight loss may not only be an effective intervention to enhance physical health but may also improve mental health outcomes and slow the rate of neuroprogressive disturbances in psychiatric disorders. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 227 REFERENCES
The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications
TLDR
Current knowledge of the neuroprogressive processes that may occur in MDD is reviewed, including structural brain consequences and potential molecular mechanisms including the role of neurotransmitter systems, inflammatory, oxidative and nitrosative stress pathways, neurotrophins and regulation of neurogenesis, cortisol and the hypothalamic–pituitary–adrenal axis modulation. Expand
The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders.
TLDR
Lithium and valproate have recently been demonstrated to robustly increase the expression of the cytoprotective protein bcl-2 in the CNS in vivo and in cells of human neuronal origin, suggesting they may have broader utility as adjunctive agents in the treatment of a variety of neuropsychiatric disorders associated with cell atrophy or loss. Expand
Minocycline: therapeutic potential in psychiatry.
TLDR
There have been promising clinical indications that minocycline may be a useful treatment in psychiatry, albeit from small trials most of which were not placebo controlled. Expand
Pathways underlying neuroprogression in bipolar disorder: Focus on inflammation, oxidative stress and neurotrophic factors
TLDR
Emerging data shows that these biomarkers may differ between early and late stages of BD in parallel with stage-related structural and neurocognitive alterations, which facilitates identification of rational therapeutic targets, and the development of novel treatment classes. Expand
Cytokines in schizophrenia and the effects of antipsychotic drugs
TLDR
Current data on the cytokine-modulating potential of antipsychotic drugs are reviewed and the possible mechanisms underlying antipsychotics' potential to influence the cytokin networks and the most relevant aspects of this activity are discussed. Expand
Inflammation in Patients with Schizophrenia: The Therapeutic Benefits of Risperidone Plus Add-On Dextromethorphan
TLDR
PANSS scores and plasma IL-1β levels significantly decreased, but plasma TNF-α and BDNF levels significantly increased after 11 weeks of Risp treatment, suggesting Risp+ DM was more beneficial and less toxic than Risp-only treatment. Expand
Neuroinflammation in schizophrenia especially focused on the role of microglia
TLDR
The inhibitory effects of some typical or atypical antipsychotics on the release of inflammatory cytokines and free radicals from activated microglia, both of which are not only directly toxic to neurons but also cause a decrease in neurogenesis as well as white matter abnormalities in the brains of the patients with schizophrenia. Expand
Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology
TLDR
An updated overview of the connections between the immune and inflammatory alterations and the aforementioned hypotheses in schizophrenia is provided, finding that schizophrenia is associated with an imbalance in inflammatory cytokines. Expand
Treating patients with schizophrenia deficit with erythropoietin?
TLDR
The findings suggest that several EPO cerebral potential properties may be relevant for schizophrenia treatment, such as neurotransmission regulation, neuroprotection, modulation of inflammation, effects on blood–brain barrier permeability and effects on oxidative stress and neurogenesis. Expand
Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development
TLDR
Converting data implicate mitochondrial dysfunction as an important component of the pathophysiology of bipolar disorder and clinical trials of individual MMs as well as combinations are warranted. Expand
...
1
2
3
4
5
...